Spot on LFC
WP has appeared to talk up his credentials but if you look at his experience, it is really in a few big pharma companies. Nothing related to Medical devices or the cardiac valve market. He gives some ok presentations but an objective analysis of the content reveals massive gaps.
In my opinion Medtronic, Edwards and other execs can see beyond the hype in terms of the time, funding and risks with the valve and delivery system and will let AVR keeping rolling
IMO
Spot on LFCWP has appeared to talk up his credentials but if you...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.15 |
Change
-0.250(2.40%) |
Mkt cap ! $214.5M | |||
| Open | High | Low | Value | Volume |
| $10.57 | $10.59 | $9.90 | $181.3K | 17.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 720 | $10.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.35 | 3407 | 1 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |